Genetic Signatures Ltd. · ASX:GSS

Genetic Signatures — Bioshares Biotech Summit 2015

14 slides from Genetic Signatures's conference presentation, July 2015

  1. Slide 1: Bioshares Presentation July 2015

    For personal use only Bioshares Presentation July 2015

  2. Slide 2: Disclaimer

    DISCLAIMER For personal use only This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australia

  3. Slide 3: The GSS IPO Experience

    For personal use only THE GSS IPO EXPERIENCE:  Why IPO?  Who to Use?  Once in…  Take 2 3

  4. Slide 4: Investment Highlights

    INVESTMENT HIGHLIGHTS For personal use only Genetic Signatures is a molecular diagnostics (MDx) company operating in the global IVD (in vitro diagnostics) industry. Primary focus on supplying major hospitals and pathology laboratories in testing for infectious diseases.  Products already available

  5. Slide 5: Corporate Snapshot

    CORPORATE SNAPSHOT For personal use only Capital Structure ASX Code GSS Shares on Issue 72.9m Market Capitalisation $32.8m Share Price (at market close 17 July, 2015) $0.45 Directors & Chief Executive Nick Samaras Non-Executive Chairman John Melki Director & CEO Mike Aicher Executive Director - US P

  6. Slide 6: Technology – 3Base

    TECHNOLOGY – 3BASE™ For personal use only A transformational MDx technology enabling customers to identify a wider array of patient infections  GSS’ 3Base™ platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variation between subt

  7. Slide 7: Case Study: Major Hospital, Sydney, Australia: Pilot Study 2013

    Case Study: Major Hospital, Sydney, Australia: For personal use only Pilot Study 2013 – EasyScreen™ vs Traditional METHODS:  Primary focus of this study was to assess the clinical utility of EasyScreen™ in detecting infectious agents in 279 patient samples as compared to their existing methods  Re

  8. Slide 8: Case Study: St Vincent's Hospital (SydPath), Sydney: Evaluation Study 2014

    “I find that the fast turnaround time and the number of targets tested in the EasyScreenTM assays allow me to more rapidly identify highly infectious agents, potentially stopping the spread to other healthy individuals and thereby saving the health system money.” (Dr Damien Stark) Case Study: St Vin

  9. Slide 9: Competitor Environment

    COMPETITOR ENVIRONMENT For personal use only Table 1 opposite explores the global competitive environment in which GSS operates for infectious disease products, focusing on enteric (otherwise known as or gastroenteritis) screening. Table 1 incorporates the major criteria utilised by global customers

  10. Slide 10: EasyScreen Product Development Pathway

    EASYSCREEN™ PRODUCT DEVELOPMENT PATHWAY For personal use only Experimental & Analytical Validation Clinical & Regulatory Validation & Release (i) (ii) (iii) (iv) (i) (ii) (iii) (iv) Enteric Kits Respiratory MRSA STI Tuberculosis Meningitis Each product goes through extensive development and beta tes

  11. Slide 11: Commercialisation Progress

    COMMERCIALISATION PROGRESS For personal use only Australia  Currently in market with major hospital and pathology group customers  Testing for 22 causes of gastroenteritis  Testing for 15 causes of viral respiratory disease  Next new product in beta testing with customer Western Europe  Establi

  12. Slide 12: Summary

    SUMMARY For personal use only  EasyScreen™ Respiratory & Enteric Pathogen Detection Kits provide faster & more accurate screening for viral, bacterial and protozoan pathogens – tests are processed in hours instead of days, with fewer false positives and negatives  Products already available in Aus

  13. Slide 13: Milestones - Snapshot

    MILESTONES - SNAPSHOT For personal use only Achieved – CY 2015  IPO  Continued sales growth of enteric product line  Initial Revenues generated from second product line – Respiratory To lookout for – balance of CY 2015  Continued sales growth  Additional EU distributorships  Release of third p

  14. Slide 14: Contact

    For personal use only CONTACT: John Melki Chief Executive Officer john@geneticsignatures.com Rob Birrell Chief Financial Officer rob@geneticsignatures.com T: +61 2 9870 7580 www.geneticsignatures.com 14

Genetic Signatures — Bioshares Biotech Summit 2015 on 6ix